BioCurex Begins Development of Unique 'POINT-OF-CARE' Test For Cancer
BioCurex Inc. announced that is has started development of a 'point-of-care' RECAF test which would be available for use at the doctor's office rather than in a laboratory setting. During the past two quarters, the Company has been engaged in converting its original radioactive-labeled RECAF blood test for cancer detection into a non-radioactive, colorimetric assay. The information gathered in the format conversion strongly supports the feasibility of a 'point-of-care' blood test for cancer detection.
The RECAF 'point-of-care' system would be targeted at physicians who either suspect a malignancy at a patient's first visit or are monitoring a patient after cancer treatment. The doctor would carry out the test in their office in a matter of minutes while examining the patient. Given the necessarily lower accuracy of a 'point-of-care' test, the device will not 'cannibalize' sales of the more precise clinical laboratory tests. Rather, it will orient the physician in the diagnostic procedure and according to the reading, prompt the request of a more accurate test from a laboratory, such as the Company's RECAF serum test. This is similar to the principle whereby a more sophisticated test is utilized to confirm the results of the point-of-care pregnancy tests available in drug stores.
Other news from the department research and development
